Preemption, tort reform, and pharmaceutical claims: Part one: Who will become the pharmaceutical industry's insurers (or is it prescribing physicians and we do not know it?)
- PMID: 17948120
- PMCID: PMC2014816
- DOI: 10.1080/08998280.2007.11928337
Preemption, tort reform, and pharmaceutical claims: Part one: Who will become the pharmaceutical industry's insurers (or is it prescribing physicians and we do not know it?)
References
-
- Ruby Ledbetter v Merck & Co, Inc, 2007 WL 1181991, ∗1181991+ (Trial Order) (Tex Dist Apr 19, 2007) Order Granting Defendant's Motion for Partial Summary Judgment and Granting Expedited Appeal (No 2005-59499).
-
- Beck J, Herrmann M. Why the Texas Vioxx Decision Matters Drug and Device Law Blogspot, April 22, 2007. Available at http://druganddevicelaw.blogspot.com/2007_04_01_archive.html; accessed July 20, 2007.
-
- See Troy DE. State-Level Protection for Good-Faith Pharmaceutical Manufacturers Washington, DC: The Federalist Society, March 21, 2006.
-
- Tex Civ Prac & Rem Code, §82.007 (Vernon's 2007).
-
- See Mich Comp Laws, §600.2946(5) (immunizes manufacturers from products liability claims unless material information misrepresented or withheld from FDA); Ariz Rev Stat Ann, §12-701; NJ Stat Ann, §2A:58C–5(c); Ohio Rev Code Ann, §2307.80(C); Or Rev Stat, §30.927; Utah Code, §78-18-2 (immunizes manufacturers from punitive damages unless material information misrepresented or withheld from FDA); NC Gen Stat, §99B-6(b)(4) (compliance with FDA or other government standard a factor to be considered).
LinkOut - more resources
Full Text Sources